C2H2-type zinc-finger transcription factor; part of the gene cluster that mediates the biosynthesis of the antifungal antibiotic FR901469, an inhibitor of beta-1,3-glucansynthase, exerting antifungal activity against the pathogenes Candida albicans and Aspergillus fumigatus (PubMed:27660098). FR901469 is a cyclic depsipeptide containing 12 amino acid residues and a fatty acid chain (PubMed:27660098). Positively regulates the expression of the FR901469 biosynthesis cluster genes frbA, frbB, frbC, frbG, frbH and frbI (PubMed:27660098, PubMed:28341398). Affects also the expression of some genes involved in other metabolic pathways, including the ergosterol biosynthetic pathway, beta-1,3-glucan catabolic enzymes or chitinases (PubMed:27660098). FR901469 inhibits the activity of 1,3-beta-glucan synthase from Candida albicans and Aspergillus fumigatus (PubMed:11099224, PubMed:11099225). With minimal inhibitory concentrations (MICs) against Candida albicans and Aspergillus fumigatus of 0.63 ug/ml and 0.16 ug/ml, repectively, FR901469 displays greater inhibitory activity than other 1,3-beta-glucan synthase inhibitors such as, WF11899A, echinocandin B, aculeacin A, and papulacandin B (PubMed:11099224, PubMed:11099225). Belongs to the GLI C2H2-type zinc-finger protein family.